Kathleen Alm
Endocrinology, Diabetes & Metabolism · Independence, MONPI 1962497016
Payments from drug & device makers
Across 182 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$636
- Medtronic$261
- Lilly USA, LLC$258
- Pfizer$248
- Mannkind Corporation$143
- Radius Health, Inc.$136
- plus $921 from 17 others
What the payments were for
- Food & beverage$2,48395%
- Gifts$1195%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 86 | $636 |
| Medtronic(2 entities) | 9 | $261 |
| Lilly USA, LLC | 20 | $258 |
| Pfizer | 15 | $248 |
| Mannkind Corporation | 4 | $143 |
| Radius Health, Inc. | 2 | $136 |
| Dexcom, Inc. | 7 | $131 |
| Tandem Diabetes Care, Inc. | 4 | $116 |
| Amgen | 5 | $88 |
| Sanofi-aventis U.S. LLC | 3 | $83 |
| Abbott | 4 | $79 |
| Corcept Therapeutics | 4 | $78 |
| Boston Scientific | 3 | $56 |
| Boehringer Ingelheim | 3 | $55 |
| Nevro Corp. | 2 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Antares Pharma, Inc. | 2 | $28 |
| Novartis | 2 | $28 |
| Cequr Corporation | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| Halozyme Inc | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tymlos$121
- RYBELSUS$102
- Minimed 670G System$100
How this compares
$2,602 in reported general payments places this provider in the 50th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $99,575 |
| JardianceEmpagliflozin | 45 | $54,021 |
| MounjaroTirzepatide | 31 | $51,705 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $32,087 |
| FarxigaDapagliflozin Propanediol | 24 | $26,091 |
| RybelsusSemaglutide | 17 | $14,512 |
| TrulicityDulaglutide | 11 | $14,229 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $8,006 |
| Novolog FlexpenInsulin Aspart | 21 | $7,991 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $5,532 |
| HumalogInsulin Lispro | 14 | $5,487 |
| SynthroidLevothyroxine Sodium | 36 | $4,546 |
| NovologInsulin Aspart | 11 | $2,472 |
| Levothyroxine Sodium | 118 | $884 |
| Metformin Hcl ErMetformin Hcl | 87 | $883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $636 | $116,55982 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $258 | $71,42156 claims |
| Boehringer IngelheimJardiance | $55 | $54,02145 claims |
| AstraZenecaFarxiga | $21 | $26,09124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Independence
- Ralph DudaSpringfield$3M
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Janet McGillSaint Louis$828K
- Christopher CaseJefferson City$692K
- Gregory LedgerSpringfield$690K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Julie SilversteinSaint Louis$536K
- Ralph OiknineChesterfield$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.